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Abstract
Background: A diagnosis of tuberculosis (TB) does not mean that the disease will be treated successfully, since
death may occur even among those who are known to the health services. Here, we aimed to analyze patient
survival time from the diagnosis of TB to death, precocious deaths, and associated factors in southern Brazil.
Methods: We conducted a longitudinal study with patients who were diagnosed with TB and who died due to the
disease between 2008 and 2015 in southern Brazil. The starting point for measuring survival time was the patient’s
diagnosis date. Techniques for survival analysis were employed, including the Kaplan-Meier test and Cox’s
regression. A mixed-effect model was applied for identifying the associated factors to precocious deaths. Hazard
ratio (HR) and odds ratio (OR) with 95% confidence intervals (95% CI) were estimated. We defined p value <0.05 as
statistically significant for all statistics applied.
Results: One hundred forty-six patients were included in the survival analysis, observing a median survival time of
23.5 days. We observed that alcoholism (HR=1.55, 95% CI=1.04-2.30) and being male (HR=6.49, 95% CI=1.03-2.68)
were associated with death. The chance of precocious death within 60 days was 10.48 times greater than the
chance of early death within 30 days.
Conclusion: Most of the deaths occurred within 2 months after the diagnosis, during the intensive phase of the
treatment. The use of alcohol and gender were associated with death, revealing inequality between men and
women. This study advanced knowledge regarding the vulnerability associated with mortality. These findings must
be addressed to fill a gap in the care cascades for active TB and ensure equity in health.
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Background
Even though the treatment of tuberculosis (TB) has
been established since the late 1940s, worldwide, TB
is one of the top 10 causes of death and the leading
cause from a single infectious agent (Mycobacterium
tuberculosis) [1]. In 2019, a total of 1.4 million HIV
(human immunodeficiency virus)-negative people, in
addition to some 300,000 people living with HIV/
AIDS (PLWHA), died as a result of TB [1]. At
present, a group of 30 countries accounts for 87% of
TB cases worldwide, and Brazil is currently in 19th
place in this world ranking [1], where the incidence
of TB in 2019 was 36 cases/100,000 inhabitants, and
the mortality was 2.2 deaths/100,000 people [2].
The geographical distribution of TB deaths is marked
by inequalities and regional heterogeneities in the coun-
try, which ranges from 1.3 deaths/100,000 in the central-
west region to 2.5 deaths/100,000 in the north [3]. The
differences are more pronounced when considering the
Brazilian capitals [3]. Mortality due to TB is strongly as-
sociated with vulnerabilities and social inequalities, and
understanding this dimension of the problem is consid-
ered a fundamental strategy to elaborate public policy,
advance equity, and mitigate the suffering occasioned by
the disease, mainly in the population at risk [4].
The literature has evidenced the factors associated
with TB death such as age, being male, coinfection HIV,
diabetes mellitus, alcohol consumption, and tobacco
smoking [5–7]. Vulnerability has also been identified
with regard to lower educational level and income,
socio-economic factors, location of one’s abode, un-
employment, informal work, and homelessness [5, 8].
The association of TB deaths with failures in treatment
has been investigated; failures occur mainly because of
the side effects of drugs, vulnerabilities, non-inclusive
and/or unfriendly policies of health services, non-unique
therapeutic projects, and the absence of a link to health
professionals [9].
Although these factors are well-known in the litera-
ture, we did not observe a distinction among the studies
in relation to the time in which death occurred [4], as if
the associated factors were independent of time. TB
deaths that occur with a known diagnosis are serious
and indicate that, at some stage of the care cascade, a
gap existed that needs to be fixed to ensure the continu-
ity of treatment, successful treatment, and adequate
quality of care [10]. Thus, estimating how long patients
survive and specifically when they died during treatment,
and if this death was precocious (the first 60 days after
diagnosis [11, 12]), may contribute to improving care
and advancing the End TB strategy for disease
elimination.
Although studying the survival time of patients and as-
sociated causes is crucial for improving care and
surveillance, in practice, few studies have been per-
formed on this issue [4], mainly in Brazil where the
number of TB deaths is still high. Patients dying in the
first stage of treatment (intensive phase), i.e., a preco-
cious death, is unjustifiable and conflicting from a qual-
ity of care perspective, since the expectation is that
patients will show progressive improvement in their
health condition. Here, we aimed to analyze patient sur-
vival time from the diagnosis of TB to death, precocious
deaths, and associated factors in southern Brazil.
Methods
Study design
This was a longitudinal study that followed TB patient
survival, from the diagnosis date to the date of death
through secondary data.
Settings
The study was conducted in Curitiba, the capital of the
State of Paraná, with an estimated population of 1,971,
185 people and a demographic density of 4027.04 people
per square kilometer [13]. This is a Brazilian state capital
with a Human Development Index (HDI) of 0.823, pla-
cing Curitiba in tenth place in the national ranking. The
percentage of people considered to be poor is at 1.73%,
while 7.93% of the population is vulnerable to poverty;
the GINI Index score is 0.55 [14]. The municipality of
Curitiba had the following coefficients: prevalence of 14
cases per 100,000 people and mortality of 1.2 per 100,
000 people [15]. The deaths were clustered in the south-
ern region of the municipality and were associated with
low HDIs in the respective regions [16].
Participants, inclusion, and exclusion criteria
The participants of the study were patients with a diag-
nosis of TB, including cases of HIV coinfection, and
who died due to disease between 2008 and 2015 consid-
ering causes A15.0 to 19.0 and B20.0 according to the
International Classification of Diseases and Related
Health Problems 10 (ICD-10). The criteria defined for
diagnosis in Brazil are based on the recommendations of
the Ministry of Health, which include medical history,
physical examination, microbiological examination (spu-
tum or some other appropriate sample) through micros-
copy or GeneXpert MTB/RIF assay (when available), and
culture [17]. The certification of the cause of death is
based mainly on a clinical evaluation by a physician who
was following the patient or necropsy when patients died
without medical assistance or in cases where the phys-
ician who provided assistance was unable to establish a
diagnosis of the cause of death [18].
The basic treatment of sensitive TB (when the patient
is not resistant to any of these drugs) was performed
with rifampicin, isoniazid, pyrazinamide, and ethambutol
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for at least 6 months. If the patient was resistant to one
of these drugs, the therapeutic regimen was changed and
the treatment time was increased to 18 months [17]. We
excluded patients when there was no record of the dates
of diagnosis and death. Survival analysis was performed
considering the difference between these dates.
Data source and measurement
Data were obtained from the Mortality Information Sys-
tem—Sistema de Informação sobre Mortalidade (SIM),
and the Notifiable Diseases Information System—Sis-
tema de Informação de Agravos de Notificação (SINAN)
through the Secretariat of Health of the State of Paraná
(SESA). We estimated a patient’s survival time consider-
ing the total time (in days) that elapsed between the date
on which the diagnosis of TB was confirmed and the
date of death as a result of TB. Once we estimated the
survival time, in sequence, we also identified the preco-
cious deaths and associated factors. All patients were
considered to estimate the survival time.
Quantitative and qualitative variables under study
Table 1 shows all independent variables considered for
the study. These variables organized according to socio-
demographic characteristics, comorbidities, and informa-
tion about the diagnosis and treatment of the patients;
their classes are also described.
Data linkage
A record linkage was necessary to join the SINAN and
the SIM considering a deterministic and probabilistic
method [19]. The first step of the linkage was performed
from the identification of the common identifier to both
systems, which was the date of diagnosis and mother’s
name of the patients. In the first step, we used the func-
tions (PROCV) provided in the software Microsoft® Of-
fice Excel 2016.
For unpaired records in this phase, in accordance with
literature [19], a probabilistic linkage using automated
procedures was applied in order to identify the probabil-
ity of a pair of records belonging to the same individual.
Each death case identified in the SIM was matched to its
respective case in the SINAN. The linkage was necessary
for more consistency and completeness of data from pa-
tients followed up in the study. The SIM has more
current and reliable information about the deaths than
the SINAN, and many cases the SINAN was out of date
regarding the death record and the dates were missing,
which is relevant to estimating survival time. The date of
diagnosis, clinical information, and treatment were vari-
ables contained only in the SINAN. All probabilistic step
processing was performed using R Studio® version 4.0.3.
Statistical methods
We applied descriptive statistics to obtain the absolute
values and percentage frequencies of the categorical vari-
ables. In the case of continuous variables (time in days
and age), we obtained the minimum and maximum
values, arithmetic mean, median, and standard deviation
(SD). The statistical analysis was performed in two
phases and with different objectives. In the first one,
with the objective of analyzing the survival time of pa-
tients and associated factors, we implemented the Cox
proportional hazards regression model [20–22]. A de-
scriptive analysis was carried out and the survival time
was estimated for each factor under study, which were
selected by statistical and clinical criteria. We elaborated
the Kaplan-Meier plot for these factors [23], and in the
survival analysis no outcome was censored, since the in-
formation of deaths due to TB was available for all study
patients. The survival analysis was used to estimate the
survival time among all patients under investigation.
Before introducing the variables into the model, we
verified multicollinearity using the variance inflation fac-
tor (VIF) as the diagnostic criterion [24]. In order to as-
sess the interaction effect between the exploratory
variable considered in this phase, interaction plots were
constructed for each pair of independent variables. Inter-
action effects occur when an independent variable, be-
yond affecting the dependent variable, also influences
the value of another independent variable, which re-
quires a more complex and robust analysis [25]. In the
analysis, the occurrence of non-parallel lines in the re-
spective plots was considered as the existence of an
interaction [26].
Subsequently, we elaborated the Cox proportional
hazards regression model with the associated factors
[26] with and without interactions. To verify the
consistency of the model and the non-violation of as-
sumptions about the analysis performed, we evaluated
the proportional hazard for the regression model with
the chi-squared goodness of fit, following Schoenfeld
[27]. Finally, we performed an analysis of the model
residuals and the quality of the final adjustment [27].
Hazard ratio (HR) was calculated with 95% confidence
intervals.
In the second phase, a mixed-effects model (mixed
model) [28] was used to identify the factors associated
with precocious deaths. Precocious deaths were catego-
rized as yes or no, considering specifically two periods,
i.e., 30 or 60 days counted from the diagnosis date.
The independent variables of fixed effects were type of
entry (new case, relapse), TB-HIV coinfection (yes, no),
alcoholism (yes, no), gender (male, female), age (years),
and clinical form (pulmonary, extrapulmonary). For a
random effect related to the patients, we assumed a nor-
mal distribution with a mean of 0 and constant variance.
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Regarding the second phase, a generalized additive
model for location, scale, and shape (GAMLSS) model
was selected, because this model assumes that obser-
vations yi for i = 1,..., n with the conditional
probability density function f (yi | θi) over θionde θi
= (θi1,... θip) is a vector of parameters of size p, each
one related to a set of independent variables. It also
assumes a monotonous relation function, given by g
Table 1 Independent variables under study
Categories Independent variables Classes





Educational level 8 years of schooling or more
7 years of schooling or less
Marital status Married/common-law marriage
Single/widowed/separated or divorced








Aggravation—use of alcohol No
Yes
Aggravation—diabetes mellitus (DM) No
Yes




Medication used: rifampicin Yes
No
Medication used: isoniazid Yes
No
Medication used: pyrazinamide Yes
No
Medication used: ethambutol Yes
No
Medication used: streptomycin Yes
No




aVariables from the first database Mortality Information System Sistema de Informação sobre Mortalidade (SIM)
bVariables from the second database Sistema de Informação de Agravos de Notificação (SINAN)
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(.), which relates the kth parameter θk with the
exploratory variables of the model [29, 30].
In this analysis, a maximum of four parameters was
required (p = 4), usually characterized by position (θ1 =
μ), scale (θ2 = σ), asymmetry (θ3 = υ), and kurtosis (θ4
= τ). While the first two population parameters, repre-
sented by μ and σ, are referred to in the literature by
position (or location) and scale parameters, respectively,
the last two υ and τ are called shape parameters.
According to this assumption, we have the following
models [31]:
Parameters of position and scale
g1 μð Þ ¼ n1 ¼ X1β1 þ Σ J1j¼1Z j1γ j1;








g3 νð Þ ¼ n3 ¼ X3β3 þ Σ j3j¼1Z j3γ j3;





where μ, σ, υ, τ, and xjk for j = 1,…, Jk ek = 1,2,3,4 are
vectors of length n, βk = (β1k,… βJ′kk) is a vector of size
parameters J′k, Xk and Zk are matrices of fixed, known in-
dependent variables and of orders n x J′k and n x qjk, re-
spectively. Finally, γjk is a qjk-dimensional random
variable [31]. For all parameters of the final model, the
odds ratio (OR) was calculated with its respective 95%
confidence interval. We defined p value <0.05 as statisti-
cally significant for all statistics employed. The power of
the final models obtained from the adjustments was calcu-
lated through Monte Carlo simulations. Data analysis was
performed using the program R version 4.0.1.
Results
Participants
A total of 205 cases were identified, and when the record
linkage between the SIM and the SINAN was applied,
179 cases (87.3%) were potentially eligible. After applica-
tion of the inclusion and exclusion criteria, including a
high enough level of information that allowed follow-up
of the patients retrospectively, a total of 146 patients
were considered for the study. In Fig. 1, we show the
flow chart presenting the number of individuals at each
stage of the study.
Descriptive data
Among the participants of the study, 84 (57.5%) had a
diagnosis of TB and 62 (42.5%) were diagnosed with TB/
HIV coinfection. The descriptive results are presented in
Table 2, in which 114 (78.1%) were male. The white race
was most prevalent (96 cases; 65.8%), and the mean age
was 47 (minimum 20, maximum 83, median = 46, and
SD = 14). The most common clinical presentation was
pulmonary TB, with 106 cases (72.6%). There were in
total 122 new cases (83.6%) and, in 124 of the cases
(84.9%), the diagnosis was confirmed by radiographic
examination. In Table 2, we also can observe the propor-
tion of the variables that were not completed satisfactor-
ily in the SINAN, indicated as “not reported” in the
Table 2.
Statistics from survival analysis
The median survival from diagnosis to death was 23.5
days, with a minimum survival time of 2 days and
Fig. 1 Flow chart of deaths analyzed in the study
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Table 2 Characteristics of the patients who died due to TB, Curitiba-Brazil
Variables Categories All deaths
N (146) (%)
Coinfection (basic cause)a Yes (TB/HIV) 62 42.5
No (only TB) 84 57.5
Gender (14)a Female 32 21.9
Male 114 78.1
Ethnicity (133)a White or oriental 96 65.8
Afrodescendant 40 27.4
Not reported 10 6.8
Years of schoolinga 0-7 years of schooling 84 57,5
8 or more years of schooling 42 28,8
Not reported 20 13.7
Marital statusa Married/common-law marriage 46 31.5
Single/widowed/separated or divorced 84 57.5
Not reported 16 11.0
Type of entryb New case 122 83.6
Re-entry or retreatment 24 16.4
Not reported 0 0
Inpatient treatmentb No 115 78.8
Yes 16 11.0
Not reported 15 10.2
X-ray confirmation of diagnosisb No 22 15.1
Yes/suspicious 124 84.9
Clinical formb Pulmonary 106 72.6
Extrapulmonary 40 27.4
Alcoholismb No 90 61.7
Yes 50 34.2
Not reported 06 4.1
Diabetes mellitus (DM)b No 136 93.1
Yes 03 2.1
Not reported 07 4.8
Microscopyb Negative 40 27.4
Positive 81 55.5
Not reported 25 17.1
Sputum culture (40)b Negative 20 13.7
Positive 20 13.7
Not reported 106 72.6
Rifampicinb No 06 4.1
Yes 128 87.7
Not reported 12 8.2
Isoniazidb No 06 4.1
Yes 128 87.7
Not reported 12 8.2
Pyrazinamideb No 06 4.1
Yes 128 87.7
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maximum of 1688 days; the SD was 174.6 days and the
mean was 73 days. The survival time according to each
factor considered for the Cox proportional hazards is
shown in Table 3. We found that the relapse cases were
those with the highest average survival time; however,
they were also the cases with the greatest dispersion in
the studied population. Among the new cases, the sur-
vival time was 47.89 days and PLWHA had a longer sur-
vival time when compared to those without HIV
infection. Additionally, patients with the extrapulmonary
form presented a lower survival time when compared to
those with pulmonary TB.
Table 2 Characteristics of the patients who died due to TB, Curitiba-Brazil (Continued)
Variables Categories All deaths
N (146) (%)
Not reported 12 8.2
Ethambutolb No 37 25.3
Yes 97 66.5
Not reported 12 8.2
Streptomycinb No 131 89.7
Yes 03 2.1
Not reported 12 8.2
Ethionamideb No 132 90.4
Yes 01 0.7
Not reported 13 8.9
Medication used: other drugsb No 122 83.6
Yes 07 4.8
Not reported 17 11.6
Directly observed therapy (DOT)b No 18 12.3
Yes 114 78.1
Not reported 14 9.6
aVariables from the first database Mortality information system Sistema de Informação sobre Mortalidade (SIM)
bVariables from the second database Sistema de Informação de Agravos de Notificação (SINAN)


















New case 122 47.89 67.83 7.00 21.00 60.25 349
Relapse 24 200.96 384.39 20.75 80.50 127.50 1688
TB/HIV coinfection
No 84 48.44 79.66 7.00 21.00 58.75 513
Yes 62 106.39 248.89 9.25 36.50 100.50 1688
Alcoholism
No 90 70.40 123.24 9.25 27.00 87.50 1008
Yes 50 78.92 246.31 7.25 23.50 49.75 1688
Gender
Female 32 69.72 114.64 7.75 21.00 65.75 513
Male 114 73.98 188.55 8.00 25.00 81.00 1688
Clinical form
Pulmonary 106 77.01 199.48 7.25 23.50 77.00 1688
Extrapulmonary
40 62.55 78.55 8.75 24.50 91.25 310
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When the factors were considered according to quar-
tiles, in the first quartile, the variables mostly had 7 to 9
days of survival time. The second quartile, which repre-
sents 50% of the sample, ranged from 21 to 80.50, with
the majority remaining between 21 and 27 days.
Figure 2 shows the curves obtained through the
Kaplan-Meier survival analysis of the factors selected for
the Cox model and the survival time of the continuous
variable age.
Figure 3 shows the interaction plots for each pair of
explanatory variables according to survival time.
The results of the survival analysis are shown in Table
4. Before performing the model, we evaluated the multi-
collinearity of the potential explanatory variables. All the
variables had a VIF value that ranged from 1.11 to 1.42,
which meant the absence of multicollinearity among
them. Through the analysis, some possible interactions
between the explanatory variables (Supplementary Ma-
terial 1) were identified in the study, specifically between
TB/HIV coinfection and gender and between age and
gender. These interactions were included in the Cox
proportional hazards regression model.
The model indicates that the variables associated with
TB death were cases of relapse (HR = 0.37, 95% CI =
0.22-0.63), alcoholism (HR = 1.55, 95% CI = 1.04-2.30),
male patients (HR = 6.49, 95% CI = 1.03-2.68). Variables
with interactions were TB/HIV coinfection and male
patients as well as age and male patients.
Regarding the variables without interactions, TB deaths
in relapse cases were 0.3 times higher than in new cases
and the individuals classified as suffering from alcoholism
showed 1.55 more risk for the mortality outcome in their
treatment. When considering the explanatory variables
that presented interactions, male individuals with TB/HIV
coinfection had a risk of death that was 0.5 times lower
than that for male individuals without TB/HIV coinfec-
tion. Female individuals with TB/HIV coinfection had a
risk of death that was 1.54 times higher than that for fe-
male patients without TB/HIV coinfection, regardless of
whether we considered people of the same age in these
comparisons. Still, in this comparison of groups, when we
examined only individuals without coinfection, male pa-
tients had a risk of death that was 6.49 times higher than
that of female patients.
Regarding the interaction between age and gender, a
reduction in the mortality rate in older individuals was
observed, specifically when male patients were compared
with female patients. In this sense, at the age of 30, men
had a risk of death that was 2.74 higher than women, at
the age of 40, the risk reduced to 2.05 and, at the age 65,
it reached the value of 1.0. Thus, older men had the
same chance of the treatment outcome under analysis as
women.
To evaluate the validity of the Cox model assumptions,
we analyzed the proportional hazard for the regression
model with the chi-squared goodness of fit (Supplemen-
tary Material 2). In addition, the analysis of the residuals
of the model (Supplementary Material 3) showed no vio-
lation of the Cox model assumptions and good suitabil-
ity of the final model.
Fig. 2 Curves obtained from the Kaplan-Meier survival analysis of the explanatory variables in patients who died of TB, Curitiba-Brazil. Legend:
dispersion time according to age and survival
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Fig. 3 Interaction plots for each pair of explanatory variables according to survival time, Curitiba-Brazil
Table 4 Results of the Cox proportional hazards regression model of patients who died from TB and associated factors, Curitiba-
Brazil
Explanatory variables Coefficient Hazard ratio 95% CI P value
Type of entry
New case 1 1
Relapse −0.98 0.37 0.22-0.63 < 0.01
TB/HIV coinfection
No 1 1
Yes 0.43 1.54 0.74-3.20 0.24
Alcoholism
No 1 1
Yes 0.44 1.55 1.04-2.30 0.03
Gender
Female 1 1
Male 1.87 6.49 1.46-28.80 0.01
Age 0.02 1.02 0.99-1.04 0.08
Clinical form
Extrapulmonary 1 1
Pulmonary 0.01 1.01 0.67-1.52 0.97
TB/HIV coinfection and gender
Without coinfection and female 1 1
With coinfection and male −1.14 0.32 0.13-0.78 0.01
Age and gender (male) −0.03 0.97 0.94-0.99 0.03
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Statistics from the mixed-effect model application
Regarding precocious deaths, Table 5 shows the results
obtained from the mixed-effect model application. Ac-
cording to the findings, patients who were alcoholic had
a chance of precocious death 17.93 times greater than
those who were not. Additionally, the chance of preco-
cious death within 60 days was 10.48 times greater than
the chance of early death within 30 days. We also ob-
served that relapse seemed to have a protective effect re-
garding death.
Discussion
We aimed to analyze patient survival time with TB, from
diagnosis to death, precocious deaths and associated fac-
tors in southern Brazil. The findings show that the me-
dian survival from diagnosis to death among those who
died from TB was 23.5 days, i.e., 67.8 days in new cases
and 384.4 in relapses.
Regarding patient survival time, the findings show that
most of the deaths occurred within 2 months. Some
studies [11, 12, 32] have investigated the phenomenon of
precocious death among patients with TB, and one such
study observed similar results with a median survival
time of 21 days in Korea [32]. Another study found that
19% of patients died within 7 days and 41% died within
the first month after the start of treatment for TB [12].
Another study, undertaken in Africa that used the begin-
ning of treatment as the zero point for estimating sur-
vival time, found a mean of 2 months in 53.3% among
people who started their TB treatment, and, in this case,
the mortality among HIV-positive people was higher
than that among people who were HIV negative or
whose HIV status was unknown [18].
Regarding associated factors with survival time for all
patients and when the interactions were not considered,
the TB deaths were associated with relapse, alcoholism,
and male gender. When the variables TB/HIV coinfec-
tion and gender were considered together, we observed
that male patients with coinfection presented a lower
risk of TB death; on the other hand, female patients with
TB/HIV had a higher risk of death, which we
hypothesize as indicating inequality between the genders
and which should be investigated through new studies.
When we analyzed only the cases of precocious deaths
through mixed-effect models, patients who were alco-
holic had a greater chance of dying precociously than
those who were not, which has been evidenced in the lit-
erature because they tend to have lower compliance with
treatment. However, a curious finding was that the
chance of precocious death within 60 days was 10.48
times greater than the chance of early death within 30
days, which indicates a gap in the care cascade, specific-
ally in the phase of intensive therapy coming to an end
(provision for TB new cases), increasing the chances of
patients abandoning treatment.
The findings also indicate that new cases tended to die
more precociously when compared to relapse cases. One
hypothesis is that, in Brazil, the health services have pri-
oritized directly observed treatment short course (DOTS)
in the intensive phase of treatment, mainly in settings
with very poor and limited resources, which might ex-
plain the risk of death 60 days after diagnosis [33].
DOTS has been defined as a priority for patients with a
relapse in these settings, since they can spread
multidrug-resistant TB (MDR-TB) (resistance to the two
main drugs used in treatment, rifampicin and isoniazid)
and therefore the follow-up strategy must be systematic
Table 5 Mixed-effect model of the associated factors with precocious deaths due tuberculosis, Curitiba-Brazila
Estimate Std. error Odds ratio 95% CI P value
Intercept 0.94 2.98 0.75
Type of entry
Relapse −4.71 1.85 <0.01 0.01-0.34 0.01**
TB/HIV coinfection
Yes −1.99 1.47 0.13 0.01-2.44 0.17
Alcoholism
Yes 2.88 1.39 17.93 1.16-276.58 0.03**
Gender
Male −2.32 1.51 0.09 0.005-1.89 0.12
Age 004 0.04 1.04 0.95-1.14 0.34
Clinical form
Pulmonary 0.63 1.39 1.87 0.12-28.99 0.65
Diagnosis time (60 days) 2.35 0.66 3.58 2.89-10.48 <0.01**
**p value <0.05
aPower of test—54.00% (95% CI 39.32; 68.19) based on 50 Monte Carlo simulation
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and rigorous, avoiding a potential epidemic of MDR-TB
in vulnerable territories [34]. MDR-TB is a concern be-
cause of the high cost of the treatment, its toxicity and
the poor outcomes with available therapies [35].
Regarding DOTS, in the city under study, the average
coverage of DOTS was 55%, [36], which reinforces our
hypotheses that the adoption of selective DOTS occurs
for specific periods during treatment or in patients who
have relapsed. The coverage of DOTS is low in Brazil,
which might explain why the success of treatment is still
lower than recommended by the World Health
Organization, i.e., near 71% when the goal is higher than
85% [1]. In Brazil, of every 10 people who begin treat-
ment, at least one abandons the use of medications,
thereby increasing the risk of MDR-TB and death [37].
Regarding the influence of both alcohol consumption
and TB mortality, some studies have demonstrated simi-
lar results. A study carried out in the same region as the
present study indicated a problem with alcoholism, re-
vealing an association between unsuccessful outcomes
and this health condition; this finding confirms the im-
portance of screening TB patients for alcohol consump-
tion [38]. One meta-analysis [39] found that alcoholism
was linked to a greater risk (RR 1.35, 95% CI, 1.09-1.68)
of contracting TB when compared to those without this
health condition. The consequences of alcoholism were
also associated with TB, such as malnutrition, mental
disease, use of other substances, and disrupted homeo-
static mechanisms [40, 41]. Additionally, alcohol use dis-
rupts the immune response, increasing susceptibility to
respiratory diseases such as TB [11, 42]. Alcoholism can
also contribute to loss of earnings, family disruption,
interpersonal violence, low self-esteem, and
stigmatization, aspects that are commonly identified
among TB patients and that caused the authors to
hypothesize about the reason for their death. Alcoholism
may compromise access to treatment, heighten the risk
of co-occurring health problems and perpetuate the
cycles of poverty, alcohol use, and TB [43].
Another aspect is the global epidemiological data on
TB, which have demonstrated a higher risk of death in
men than in women [44, 45]; however, this study evi-
denced an intriguing and complex issue. Female patients
with a diagnosis of TB/HIV coinfection had a higher risk
of death; male patients with this condition had a lower
risk. It is important to note that this comparison must
be made in people of the same sex because, when com-
paring men and women with HIV, the risk remains
higher among men.
TB and HIV are public health problems that have a
synergistic effect on each other, leading to a higher risk
of unfavorable treatment results [46]. We corroborate
this finding, although we understand that these risks are
not randomly distributed among men and women. Brazil
has achieved interesting progress in terms of access to
antiretroviral therapy for HIV patients, with a
stabilization in incidence, a reduction in opportunistic
diseases, and increased mean survival time [47]. How-
ever, studies have identified gender inequality, observing
that women with low income and schooling, who had
monogamous relationships throughout their lives, were
at risk of a delayed diagnosis of HIV/AIDS [48]; this
phenomenon was also observed in the USA, where fe-
male patients at risk of delayed HIV diagnosis were
poorer, non-urban, and possibly exposed to HIV hetero-
sexually [49], which may be associated with the findings
of the present study. There is little evidence to explain
this result regarding the gender difference from the indi-
vidual perspective in terms of TB mortality, but the re-
sults may also be associated with a low CD4 count, not
receiving antiretroviral therapy or undergoing cotrimox-
azole prophylaxis therapy, being a female sex worker, be-
ing older, and being bedridden [50, 51].
We also found that young men are at higher risk of
death than older men if we compared them with women
of the same age. Some studies have demonstrated a sig-
nificant excess of TB mortality occurring in the young
adult population [45], but, as identified in our study, sex
and age are intercepted and produce different risk effects
for death, information that is of great relevance to con-
ducting TB treatments.
The literature indicates that the efficacy of treatment
is higher than 99.9%, even for patients with HIV [52,
53], but the present study revealed that the majority of
patients died precociously. Beyond DOTS, there exists a
lack of strategies for complete recovery of patients lead-
ing to a delay in hospital admission, a lack of suitable
management of side effects, multiple morbidities (not
assessed by this study), and not assessing the risk of fail-
ure. Offering social benefits such as basic food baskets,
transportation vouchers, income generation programs,
and school integration are very important and need to
be implemented effectively to ensure the continuity of
treatment, adherence, and better life conditions [11, 54].
Because of the alarming number of failures and deaths,
the Brazilian health authorities have reinforced the im-
portance of continuing treatment until the end, initiated
in 2020 during the COVID-19 pandemic, an action on
the Internet and social media aimed at people with TB
with the goal of improving adherence and reducing the
occurrence of failures and deaths, emphasizing inclusive
DOTS for all cities [37]. The WebDOT platform has
been developed and implemented in some cities [55] as
a solution alternative for patient support and medication
monitoring over the internet during the pandemic [23].
The difficulty in accessing services at the moment of
symptom onset [32], especially in vulnerable groups or
when health service providers are not qualified to
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recognize a cough as being a clinical sign of TB, should
be borne in mind [24]. This result suggests the need for
an attention model that gives a higher value to the active
search for patients within territories, the tracking of TB
among the population at large and regular appointments
for patients living with HIV [23, 56, 57].
Brazil has a special protocol in place for monitoring
the deaths that occur with a mention of TB as one of
the causes, a protocol that, among other aims, seeks to
investigate these patients’ individual health conditions
and their access to health services. Additionally, this
protocol is used for analyzing and correcting the infor-
mation that appears in the different information systems
used, namely, the SIM, SINAN, and TB site [57]. This is
a strategic initiative to improve the qualification of the
data; however, according to evidence from the present
study, it is important to verify the phase during which
the patient died in a stratified fashion, whether the case
was being monitored by the health service and whether
this happened in an early or late phase of treatment.
This is important because, depending on the phase in
which the patient died, actions also need to be modu-
lated, as death makes us wonder whether measures and
protocols have been implemented effectively to have an
impact on TB context as well on the quality of care [58].
One of the limitations of this study is the small popu-
lation studied and very heterogeneous; therefore, the
findings are not generalizable to other contexts and
population. Other limitations are the use of secondary
data, which were entered into the form in advance, as
there were gaps in form filling or missing information.
Additionally, we did not have information regarding on-
set of clinical symptoms in patients, as this information
was not available in the SINAN. The issue of alcohol
consumption information is other bias, because the in-
formation is based on self-reports from patients or the
subjective analysis of health workers, which might influ-
ence the findings; the culture in the region may
stigmatize alcohol use in females, which was not verified
in the present study.
The methodology used by the health services to con-
firm TB deaths, in most cases, did not use the death
audit strategy or even verbal autopsy, which may be a
difficult in the certification of deaths that occur in Brazil.
Because of the restrictive information contained in the
SIM and the SINAN, we encourage the development of
new studies, mainly mixed methods research, to fill gaps
that are not well-understood.
Since the SIM and the SINAN are not interconnected,
it is difficult for health professionals and health man-
agers to follow up on patients and monitor the evolution
of their treatment, including the circumstances of death,
if associated with TB. Therefore, this study contributes
to advancing this issue in Brazil, as it is first to approach
deaths due to TB and the integration/linkage of data-
bases as a retrospective longitudinal study. Despite the
study’s limitations from both systems, they are official
sources and references to monitor and understand the
TB situation in Brazil.
We emphasize that this study has made important
contributions to understanding the real magnitude of
death due to TB, since this is still underestimated. We
used an original and specific method to link databases
and then monitor patient survival time, and we also
identified patients who died precociously due to TB.
While these patients who died due to TB remain under-
estimated and undervalued, we never will manage and
solve this problem in a proper and fair way.
Conclusion
Most of the deaths occurred within 2 months after the
diagnosis, during the intensive phase of the treatment.
The use of alcohol and gender were associated with
death, revealing inequality between men and women.
We also observed that male patients with coinfection
had a lower risk of precocious TB death and, conversely,
female patients with comorbidity had a higher risk of
early death. The findings also revealed that new cases
tended to die more precociously when compared to re-
lapse cases. The chance of precocious death within 60
days was 10.48 times greater than the chance of early
death within 30 days. This study advanced knowledge
regarding the identification of the vulnerabilities associ-
ated with mortality through a novel methodology. The
findings must be addressed to fill a gap in the care
cascades for active TB and ensure equity in health.
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